Skip to main content

On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance

Buy Article:

$43.00 plus tax (Refund Policy)

Summary.

Gasparini and Eisele (2000, Biometrics56, 609–615) propose a design for phase I clinical trials during which dose allocation is governed by a Bayesian nonparametric estimate of the dose-response curve. The authors also suggest an elicitation algorithm to establish vague priors. However, in situations where a low percentile is targeted, priors thus obtained can lead to undesirable rigidity given certain trial outcomes that can occur with a nonnegligible probability. Interestingly, improvement can be achieved by prescribing slightly more informative priors. Some guidelines for prior elicitation are established using a connection between this curve-free method and the continual reassessment method.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Bayesian nonparametric estimation; Continual reassessment method

Document Type: Research Article

Affiliations: Division of Biostatistics, School of Public Health, Columbia University, New York, New York 10032, U.S.A., Email: [email protected]

Publication date: 2002-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more